Amarantus Biosciences Inc. is an early stage biotech devoted to controlling diseases related to programmed cell death. Its lead program focuses on mesencephalic astrocyte-derived neurotrophic factor (MANF) as a therapeutic protein for conditions such as Parkinson's disease and traumatic brain injury.
Stellar Phase IIb results reported by Ophthotech Corp. for Fovista have harshed Regeneron Pharmaceuticals Inc.'s mellow just six weeks after the highly successful launch of competing product Eylea (aflibercept opthalmic solution).
A $25 million Series B financing disclosed Wednesday morning will bring the total amount invested in Rhythm Pharmaceuticals Inc. to $65 million, according to Bart Henderson, founder and president of the Boston-based company.
Detailed results from GlaxoSmithKline plc's Harmony 6 and Harmony 7 Phase III trials of albiglutide in Type II diabetes at 52 and 32 weeks presented at the American Diabetes Association Meeting in Philadelphia showed mixed results compared to positive top-line Harmony 6 results previously reported, and results consistent with a previously reported primary endpoint miss for Harmony 7.
Shares of XenoPort Inc. plunged 9.6 percent Thursday as investors frantically shorted the stock that had run up to more than $6 in anticipation of the PDUFA date for Horizant (gabapentin enacarbil) extended-release tablets for postherpetic neuralgia (PHN) in adults, an event that triggered a $10 million milestone payment from partner GlaxoSmithKline plc.
As anticipated, the FDA issued a complete response letter for Taltorvic (ridaforolimus) from Merck & Co. Inc. and Ariad Pharmaceuticals Inc. as a maintenance therapy for metastatic sarcoma.
Advaxis Inc. reported positive preliminary results from a Phase II trial of its human papillomavirus (HPV) immunotherapy product, ADXS-HPV, at the American Society of Clinical Oncology meeting in Chicago this week.
A third tranche of $23 million brings PhaseBio Pharmaceuticals Inc.'s Series B financing total to $48.4 million. The disbursement was triggered by completion of a Phase I/IIa trial of Glymera in Type II diabetes.
Stock in Cleveland Biolabs Inc. surged 63 percent following the release of results from its efficacy study of radiation countermeasure product, CBLB502, showing a nearly threefold increase in overall survival among rats exposed to a 70 percent lethal dose of radiation.
A Phase II trial of CH-4051, a product in development for rheumatoid arthritis (RA) from Chelsea Therapeutics Inc., failed to meet its primary endpoint of superiority over methotrexate.
